Cancer Database Query Results

NSCLC, Non-small Cell Lung Cancer: Click to Expand ⟱
Non-small Cell Lung Cancer
Scientific Papers found: Click to Expand⟱
5458- AF,    Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer
- in-vitro, NSCLC, NA
TrxR↓, AntiCan↓, GPx4↓, DNAdam↑, toxicity↓, eff↝,
5347- Akk,  immuno,    Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
- Human, NSCLC, NA
eff↑,
257- AL,  Cisplatin,    Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors
- in-vitro, NSCLC, A549
ROS↑, HIF-1↓, E-cadherin↑, N-cadherin↓, antiOx↓, Dose↝,
5361- almon,    Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)
- Trial, NSCLC, NA
EGFR↓, OS↑, Dose↝,
5360- almon,  BEV,    Case report: Almonertinib in combination with bevacizumab for leptomeningeal metastases from epidermal growth factor receptor-mutation non-small cell lung cancer: Case series
- Case Report, NSCLC, NA
BBB↑, Dose↝, eff↓, OS↑,
5359- almon,    Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
- Trial, NSCLC, NA
eff↑, EGFR↓,
5358- almon,    Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
- vitro+vivo, NSCLC, NA
TumMeta↓, BBB↑, EGFR↓,
5357- almon,    AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
- Trial, NSCLC, NA
EGFR↓, eff↝, OS↑,
6602- Anamu,    Dibenzyl Trisulfide Inhibits the Proliferation and Metastasis of Nsclc Via Suppressing Jak/Stat3 Signal Pathway
- vitro+vivo, NSCLC, H1299 - in-vitro, NSCLC, A549
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, BAX↑, Bcl-2↓, EMT↓, p‑STAT3↓, TumCG↓,
6399- ANE,    Anethole attenuates lung cancer progression by regulating the proliferation and apoptosis through AKT and STAT3 signaling
- vitro+vivo, NSCLC, A549
TumCP↓, TumCG↓, Apoptosis↑, DNAdam↑, Casp3↑, PI3K↓, Akt↓, STAT3↓, Ki-67↓, cl‑Casp3↑,
570- ART/DHA,    Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling
- vitro+vivo, NSCLC, A549 - vitro+vivo, NSCLC, H1299
TumCCA↑, CSCs↓, TumCI↓, TumCMig↓, TumCG↓, Wnt/(β-catenin)↓, Nanog↓, SOX2↓, OCT4↓, N-cadherin↓, Vim↓, E-cadherin↑,
5131- ART/DHA,    Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells
- in-vitro, NSCLC, ASTC-a-1
Apoptosis↑, MMP↓, Casp3↑, TumCP↓,
4678- Ash,    Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer
- vitro+vivo, NSCLC, H1975
ROS↑, AntiTum↑, CSCs↓, mTOR↓, STAT3↓, ChemoSen↑, Keap1↑, NRF2↓,
5540- BBM,    Berbamine Inhibits Cell Proliferation and Migration and Induces Cell Death of Lung Cancer Cells via Regulating c-Maf, PI3K/Akt, and MDM2-P53 Pathways
- vitro+vivo, NSCLC, NA
TumCMig↓, TumCI↓, PI3K↓, Akt↓, MDM2↓, TumCP↓, TumMeta↓,
5180- BBR,    Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth
- in-vitro, NSCLC, NA
TumCMig↓, TumCP↓, Apoptosis↑, TFAP2A↓, hTERT/TERT↓, NF-kB↓, COX2/PTGS2↓, Hif1a↓, VEGF↓, Akt↓, p‑ERK↓, Cyt‑c↑, cl‑Casp↑, cl‑PARP↑, PI3K↓, Akt↓, Raf↓, MEK↓, ERK↓,
5594- BEV,  immuno,    Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC
- Human, NSCLC, NA
eff↑,
5720- BF,    Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway
- in-vitro, NSCLC, NA
STAT3↓, CycB/CCNB1↓, CDC2↓, Mcl-1↓, survivin↓, VEGF↓, Bcl-2↓, BAX↑, Casp3↑,
5716- BF,    Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, or Pancreatic Cancer
- Trial, NSCLC, NA - Trial, PC, NA - Trial, HCC, NA
Dose↝, toxicity↓, other↓, QoL↑, OS?,
5623- Bif,    Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients
- Study, NSCLC, NA
GutMicro↑, OS↑, eff↑,
6548- BSB,    Anticancer effects of α-Bisabolol in human non-small cell lung carcinoma cells are mediated via apoptosis induction, cell cycle arrest, inhibition of cell migration and invasion and upregulation of P13K/AKT signalling pathway
- in-vitro, NSCLC, A549
AntiCan↑, Dose↝, TumCCA↑, mt-Apoptosis↑, TumCMig↓, PI3K↓, Akt↓,
5852- CAP,    Capsaicin Synergizes with Camptothecin to Induce Increased Apoptosis in Human Small Cell Lung Cancers via the Calpain Pathway
- vitro+vivo, NSCLC, NA
ChemoSen↑, Ca+2↑, cal2↑,
5942- Cela,    Celastrol elicits antitumor effects by inhibiting the STAT3 pathway through ROS accumulation in non-small cell lung cancer
- vitro+vivo, NSCLC, H460 - in-vitro, NSCLC, PC9
TumCG↓, TumCP↓, TumMeta↓, ROS↑, ER Stress↑, p‑STAT3↓, Apoptosis↑, eff↓, TumCG↓, IL6↓, other↝,
7039- Cic,    Chicoric acid targets PYGL to normalize glycogenolysis-driven glycolysis to suppress non-small cell lung cancer
- in-vitro, NSCLC, H1975 - in-vitro, NSCLC, H460
PYGL↓, Glycolysis↓, LDHA↓, lactateProd↓, GlucoseCon↓, TumCP↓,
6526- CRV,    Multi-targeted effects of D-carvone against Non-Small Cell Lung Cancer (NSCLC): A network pharmacology-based study
- Review, NSCLC, NA
TumCP↓, Wound Healing↓, Apoptosis↓,
4675- CUR,    Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines
- in-vitro, NSCLC, A549
ChemoSen↑, CSCs↓, EpCAM↓, TumCCA↓, VEGF↓, MMP9↓, toxicity↓,
6249- Cyc,    Cyclopamine tartrate, an inhibitor of Hedgehog signaling, strongly interferes with mitochondrial function and suppresses aerobic respiration in lung cancer cells
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H1299
HH↓, OCR↓, TumCP↓, Apoptosis↑, ROS↑, MMP↑, mtDam↑,
6684- DAP,  GB,    Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells
- vitro+vivo, NSCLC, H1975
PDK1 / PDPK1↓, eff↑, EGFR↓, Apoptosis↑,
4901- DCA,  Sal,    Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer
- Review, NSCLC, NA
Glycolysis↓, OXPHOS↑, PDKs↓, ROS↑, Apoptosis↑, GlucoseCon↓, lactateProd↓, RadioS↑, TumAuto↑, mTOR↓, LC3s↓, p62↑, TumCG↓, OS↑, toxicity↝, ChemoSen↑, eff↑, eff↑, Ferritin↓, CSCs↓, EMT↓, ROS↑, Cyt‑c↑, Casp3↑, ER Stress↑, selectivity↑, eff↑, TumCG↓,
6677- Deg,    Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis
- in-vitro, NSCLC, NA
Glycolysis↓, TumCG↓, Akt↓, Apoptosis↑, TumCP↓, HK2↓, PI3K↓, cMyc↓,
3215- EGCG,    Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H1299
TumCP↓, Ki-67↓, GPx4↓, ACSL4↑, Iron↑, MDA↑, ROS↑, Ferroptosis↑, eff↑, NRF2↑, HO-1↑,
4684- EGCG,    EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells
- in-vivo, NSCLC, A549
miR-485↑, CSCs↓, CD44↓,
6583- EU,    Inactivation of AKT/NF-κB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, Calu-1
tumCV↓, TumCCA↑, Casp3↑, PARP↑, Bcl-xL↓, survivin↓, Akt↓, NF-kB↓, ChemoSen↑,
6845- EVO,    Evodiamine, a Novel NOTCH3 Methylation Stimulator, Significantly Suppresses Lung Carcinogenesis in Vitro and in Vivo
- vitro+vivo, NSCLC, A549 - in-vitro, Lung, H1299
AntiCan↑, TumVol↓, NOTCH3↓, tumCV↓, TumCCA↑, TumCMig↓, CSCs↓, TumCP↓, Apoptosis↑, TumCI↓, ROS↑, TumCG↓, selectivity↑, DNMT1↓,
2496- FBZ,    Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H460
TumCG↓, selectivity↑, P53↑, IKKα↑, ER Stress↑, GRP78/BiP↑, CHOP/DDIT3↑, ATF3↑, IRE1↑, NOXA↑, ROS↑, MMP↓, Cyt‑c↑, selectivity↑, eff↝,
6969- Form,    Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer
- vitro+vivo, NSCLC, HCC827 - in-vitro, NSCLC, A549 - in-vitro, Lung, H1299
EGFR↓, Akt↓, GSK‐3β↑, TumCG↓, ChemoSen↑, Mcl-1↓, RadioS↑, tumCV↓, selectivity↑, Dose↝, Cyt‑c↑, BAX↑, Apoptosis↑, Ki-67↓, toxicity↓, chemoPv↑,
7046- GA,    Gallic acid: A promising anti-non-small cell lung cancer compound targeting early growth response protein-1 for apoptosis and ferroptosis
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H1299
TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, Apoptosis↑, Ferroptosis↑, THBS1↓, EGR1↓, TGF-β1↓, SMAD2↓, SMAD3↓, GPx4↓, ROS↑, i-MDA↑, i-Iron↑,
7047- GA,    Gallic acid-conjugated 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone induces apoptosis and downregulates PI3K/Akt signaling through VEGFR-2 targeting in non-small cell lung cancer (NSCLC)
- in-vitro, NSCLC, A549
TumCP↓, selectivity↑, AKT1↓, EP4/PTGER4↓, PDK1 / PDPK1↓, VEGFR2/KDR/Flk1↓,
7215- GBE,  Cisplatin,    Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer
- vitro+vivo, NSCLC, NA
AntiCan↑, TumAuto↑, ChemoSen↑, Iron↑, lipid-P↑, Ferroptosis↑, xCT/SLC7A11↓, GPx4↓, GSH/GSSG↓, ROS↑, NRF2↓, HO-1↓, MMP↓,
7136- GI,    [6]-shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2
- vitro+vivo, NSCLC, H1650
TumCP↓, TumCCA↑, Apoptosis↑, Akt↓, EGFR↓, STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, TumCG↓, Ki-67↓, eff↑, Dose↝,
4505- GLA,    Gamma linolenic acid suppresses hypoxia-induced proliferation and invasion of non-small cell lung cancer cells by inhibition of HIF1α
- in-vitro, NSCLC, Calu-1
TumCP↓, PCNA↓, Ki-67↓, MCM2↓, Bcl-2↓, BAX↑, cl‑Casp3↑, TumCMig↓, TumCI↓, Hif1a↓, VEGF↓,
7548- HYP,    Mechanistic evaluation of hyperoside against non-small cell lung cancer: a combined approach of network pharmacology and in vitro experimental validation
- in-vitro, NSCLC, A549
MMP9↓, cl‑Casp3↑, MAPK↑, EGFR↓, TumCP↓, p38↑, Apoptosis↑, BAX↑, ERK↓, FOXO1↓,
7547- HYP,    Hyperoside suppresses NSCLC progression by inducing ATG13-mediated autophagy and apoptosis
- vitro+vivo, NSCLC, NA
TumCMig↓, TumCP↓, TumCG↓, Apoptosis↑, TumCCA↑, TumAuto↑, ATG13↑,
7551- HYP,    Hyperoside exhibits anticancer activity in non‑small cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1
- vitro+vivo, NSCLC, NA
TumCP↓, Apoptosis↑, FOXO1↑, CCAT1↓, TumCG↓,
7554- HYP,    Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism
- in-vitro, NSCLC, A549
tumCV↓, Apoptosis↑, p‑MAPK↑, JNK↑, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, AIF↑,
7553- HYP,    Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro
- in-vitro, NSCLC, A549 - in-vitro, Nor, BEAS-2B
LC3II↑, selectivity↑, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, p‑4E-BP1↓, p‑ERK↑, tumCV↓, Apoptosis↑,
7989- itraC,    Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer
- Trial, NSCLC, NA
Dose↝, TumVol↓, angioG↓, IL1β↓, GM-CSF↓, HH∅, BioAv↝, other↝,
8014- itraC,    Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer
- vitro+vivo, NSCLC, NA
TumCP↓, TumCMig↓, ChemoSen↑, angioG↓, Hif1a↑,
8093- KAE,    Kaempferol inhibits Nrf2 signalling pathway via downregulation of Nrf2 mRNA and induces apoptosis in NSCLC cells
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H460
GSTA1↓, NQO1↓, HO-1↓, NRF2↓, ROS↑, Apoptosis↑,
8152- lamb,  TRAIL/rTRAIL,    Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-κB and Activation of Caspases and Death Receptor 4
- in-vitro, NSCLC, A549 - in-vitro, Lung, H1299
TumCD↑, cl‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓, cFLIP↓, XIAP↓, BID↑, DR4↑, p‑NF-kB↓, p‑IκB↓,
8248- LCA,    Licochalcone A Inhibits the Proliferation of Human Lung Cancer Cell Lines A549 and H460 by Inducing G2/M Cell Cycle Arrest and ER Stress
- in-vitro, NSCLC, A549 - in-vitro, Lung, H460
tumCV↓, TumCG↓, TumCCA↑, MDM2↓, CycB/CCNB1↓, cDC2↓, CDC25↓, Casp3↑, PARP↑, ER Stress↑, p‑eIF2α↑, ATF4↑, TumCP↓, selectivity↑, Bcl-xL↓, Bcl-2↓,

Showing Research Papers: 1 to 50 of 66
Page 1 of 2 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 66

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ATG13↑, 1,   PYGL↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   ATF3↑, 1,   Ferroptosis↑, 3,   GPx4↓, 4,   GSH/GSSG↓, 1,   GSTA1↓, 1,   HO-1↓, 2,   HO-1↑, 1,   Iron↑, 2,   i-Iron↑, 1,   Keap1↑, 1,   lipid-P↑, 1,   MDA↑, 1,   i-MDA↑, 1,   NQO1↓, 1,   NRF2↓, 3,   NRF2↑, 1,   OXPHOS↑, 1,   ROS↑, 12,   TrxR↓, 1,   xCT/SLC7A11↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   CDC2↓, 1,   CDC25↓, 1,   MEK↓, 1,   MMP↓, 4,   MMP↑, 1,   mtDam↑, 1,   OCR↓, 1,   Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↑, 1,   AKT1↓, 1,   cMyc↓, 1,   GlucoseCon↓, 2,   Glycolysis↓, 3,   HK2↓, 1,   lactateProd↓, 2,   LDHA↓, 1,   PDK1 / PDPK1↓, 2,   PDKs↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 9,   p‑Akt↓, 1,   Apoptosis↓, 1,   Apoptosis↑, 19,   mt-Apoptosis↑, 1,   BAX↑, 5,   Bcl-2↓, 5,   Bcl-xL↓, 2,   BID↑, 1,   cl‑Casp↑, 1,   Casp3↑, 9,   cl‑Casp3↑, 3,   Casp7↑, 1,   Casp8↑, 1,   Casp9↑, 2,   cFLIP↓, 1,   Cyt‑c↑, 5,   DR4↑, 1,   Ferroptosis↑, 3,   hTERT/TERT↓, 1,   JNK↑, 1,   MAPK↑, 1,   p‑MAPK↑, 1,   Mcl-1↓, 2,   MDM2↓, 2,   NOXA↑, 1,   p38↑, 1,   survivin↓, 2,   TumCD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,   other↝, 2,   tumCV↓, 6,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 4,   GRP78/BiP↑, 1,   IRE1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3II↑, 1,   LC3s↓, 1,   p62↑, 1,   TumAuto↑, 3,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 2,   DNMT1↓, 1,   P53↑, 1,   PARP↑, 2,   cl‑PARP↑, 2,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CycB/CCNB1↓, 2,   cycD1/CCND1↓, 1,   TFAP2A↓, 1,   TumCCA↓, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑4E-BP1↓, 1,   CD44↓, 1,   cDC2↓, 1,   CSCs↓, 6,   EMT↓, 2,   EP4/PTGER4↓, 1,   EpCAM↓, 1,   ERK↓, 2,   p‑ERK↓, 1,   p‑ERK↑, 1,   FOXO1↓, 1,   FOXO1↑, 1,   GSK‐3β↑, 1,   HH↓, 1,   HH∅, 1,   MCM2↓, 1,   mTOR↓, 2,   p‑mTOR↓, 1,   Nanog↓, 1,   NOTCH3↓, 1,   OCT4↓, 1,   p‑P70S6K↓, 1,   PI3K↓, 5,   SOX2↓, 1,   STAT3↓, 4,   p‑STAT3↓, 2,   TumCG↓, 15,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   cal2↑, 1,   CCAT1↓, 1,   E-cadherin↑, 2,   Ki-67↓, 5,   miR-485↑, 1,   MMP9↓, 2,   N-cadherin↓, 2,   SMAD2↓, 1,   SMAD3↓, 1,   TGF-β1↓, 1,   THBS1↓, 1,   TumCI↓, 6,   TumCMig↓, 10,   TumCP↓, 21,   TumMeta↓, 3,   Vim↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   ATF4↑, 1,   EGFR↓, 8,   EGR1↓, 1,   HIF-1↓, 1,   Hif1a↓, 2,   Hif1a↑, 1,   VEGF↓, 4,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   GM-CSF↓, 1,   IKKα↑, 1,   IL1β↓, 1,   IL6↓, 1,   p‑IκB↓, 1,   NF-kB↓, 2,   p‑NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   ChemoSen↑, 8,   Dose↝, 8,   eff↓, 2,   eff↑, 10,   eff↝, 3,   RadioS↑, 2,   selectivity↑, 8,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 8,   Ferritin↓, 1,   GutMicro↑, 1,   hTERT/TERT↓, 1,   IL6↓, 1,   Ki-67↓, 5,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiCan↑, 3,   AntiTum↑, 1,   chemoPv↑, 1,   OS?, 1,   OS↑, 5,   QoL↑, 1,   toxicity↓, 4,   toxicity↝, 1,   TumVol↓, 2,   Wound Healing↓, 1,  
Total Targets: 184

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:19  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page